| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Sincalide (CCK-8) is a cholecystokinetic drug used to treat cholecystitis and to diagnose disorders of the gallbladder and pancreas. It is cholecystokinin's 8-amino acid C-terminal fragment. The brain and intestines contain the octapeptide hormone sincalide. It is secreted from the mucosa of the stomach and causes the gallbladder to release bile and the pancreas to release digestive enzymes.
| ln Vitro |
Sincalide (Cholecystokinin octapeptide, CCK‐8), a novel cardiovascular hormone, significantly inhibits myocardial fibrosis in noninfarcted regions. Additionally, CCK-8 is beneficial in the fight against apoptosis, inflammation, and collagen deposition. In part, CCK-8 prevents Ang II-induced apoptosis in H9c2 cardiomyoblasts by activating the CCK1 receptor and PI3K/Akt (phosphatidylinositol-3 kinase/protein kinase B) signaling pathway[3].
|
|---|---|
| ln Vivo |
Sincalide (Cholecystokinin octapeptide, CCK‐8) (i.p.; 50 μg/kg/d; for 4 weeks) reduces fibrosis in the noninfarcted areas and delays the development of heart failure and left ventricular remodeling in a MI rat model[4].
|
| Cell Assay |
Cell Line: H9c2 cells
Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L Incubation Time: 24 h Result: Attenuated Ang II‐induced toxicity in H9c2 cells |
| Animal Protocol |
MI rat model
50 μg/kg i.p.; 50 μg/kg/d; for 4 weeks |
| References |
|
| Molecular Formula |
C49H62N10O16S3
|
|---|---|
| Molecular Weight |
1143.26898
|
| Exact Mass |
1142.35
|
| Elemental Analysis |
C, 51.48; H, 5.47; N, 12.25; O, 22.39; S, 8.41
|
| CAS # |
25126-32-3
|
| Related CAS # |
Sincalide ammonium; 70706-98-8
|
| Appearance |
Solid powder
|
| SMILES |
CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
|
| InChi Key |
IZTQOLKUZKXIRV-YRVFCXMDSA-N
|
| InChi Code |
InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
|
| Chemical Name |
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
|
| Synonyms |
CCK-8S; CCK 8S; CCK8S; Kinevac; CCK-8; CCK 8; CCK8
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~50 mg/mL (~43.7 mM)
DMF: ~50 mg/mL (~43.7 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.19 mM) (saturation unknown) in 10% DMF 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8747 mL | 4.3734 mL | 8.7468 mL | |
| 5 mM | 0.1749 mL | 0.8747 mL | 1.7494 mL | |
| 10 mM | 0.0875 mL | 0.4373 mL | 0.8747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00706381 | Completed | Drug: Sincalide Drug: Ursodiol Drug: Placebo |
Healthy Volunteers | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
June 23, 2008 | Phase 3 |
| NCT04567667 | Completed | Drug: [14C] BMS-986278 Drug: Kinevac® |
Healthy Volunteers | Bristol-Myers Squibb | October 15, 2020 | Phase 1 |
| NCT00004414 | Completed | Drug: sincalide | Cholestasis | University of Michigan | September 1997 | Not Applicable |
| NCT02507167 | Completed | Drug: Supplement: mixed meal Drug: Rifampin |
Gastrointestinal Hormones | University Medicine Greifswald | November 2012 | Phase 1 |
| NCT00685477 | Completed | Drug: Experimental Sequence ABC Drug: Experimental Sequence ACB |
Healthy | Temple University | May 2008 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA